AU2016325556B2 - Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate - Google Patents

Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate Download PDF

Info

Publication number
AU2016325556B2
AU2016325556B2 AU2016325556A AU2016325556A AU2016325556B2 AU 2016325556 B2 AU2016325556 B2 AU 2016325556B2 AU 2016325556 A AU2016325556 A AU 2016325556A AU 2016325556 A AU2016325556 A AU 2016325556A AU 2016325556 B2 AU2016325556 B2 AU 2016325556B2
Authority
AU
Australia
Prior art keywords
subject
liver disease
phenylacetate
ornithine
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016325556A
Other languages
English (en)
Other versions
AU2016325556A1 (en
Inventor
Cristina R. Bosoi
Chantal BÉMEUR
Marc-André CLÉMENT
Mariana Macedo Oliveira
Christopher F. Rose
Mélanie TREMBLAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocera Therapeutics Inc
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Publication of AU2016325556A1 publication Critical patent/AU2016325556A1/en
Application granted granted Critical
Publication of AU2016325556B2 publication Critical patent/AU2016325556B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016325556A 2015-09-25 2016-09-22 Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate Active AU2016325556B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233002P 2015-09-25 2015-09-25
US62/233,002 2015-09-25
PCT/US2016/053176 WO2017053613A1 (en) 2015-09-25 2016-09-22 Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate

Publications (2)

Publication Number Publication Date
AU2016325556A1 AU2016325556A1 (en) 2018-03-01
AU2016325556B2 true AU2016325556B2 (en) 2023-02-16

Family

ID=58387333

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016325556A Active AU2016325556B2 (en) 2015-09-25 2016-09-22 Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate

Country Status (7)

Country Link
US (1) US20200206174A1 (https=)
EP (1) EP3352748A4 (https=)
JP (1) JP6989495B2 (https=)
AU (1) AU2016325556B2 (https=)
CA (1) CA2998490A1 (https=)
HK (1) HK1257679A1 (https=)
WO (1) WO2017053613A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE035921T2 (en) 2009-04-03 2018-05-28 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
ES2769000T3 (es) 2014-11-24 2020-06-24 Ucl Business Ltd Tratamiento de enfermedades asociadas con la activación de células estrelladas hepáticas utilizando terapias reductoras de amoníaco
CN108366983A (zh) * 2015-11-13 2018-08-03 欧塞拉治疗有限公司 L-鸟氨酸苯乙酸盐制剂
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MX2020001765A (es) 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica.
WO2019226786A1 (en) * 2018-05-22 2019-11-28 Duke University Compositions and methods for treating neurodegenerative disorders with rifaximin
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
SG11202111509PA (en) * 2019-05-09 2021-11-29 Ocera Therapeutics Inc Methods of assessing and treating hepatic encephalopathy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056794A1 (en) * 2004-11-26 2006-06-01 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
WO2010115055A1 (en) * 2009-04-03 2010-10-07 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
WO2010144498A2 (en) * 2009-06-08 2010-12-16 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
CN1304723A (zh) * 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006056794A1 (en) * 2004-11-26 2006-06-01 Ucl Business Plc Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy
WO2010115055A1 (en) * 2009-04-03 2010-10-07 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
WO2010144498A2 (en) * 2009-06-08 2010-12-16 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AL SIBAE M.R. et al., "Current trends in the treatment of hepatic encephalopathy", Therapeutics and Clinical Risk Management, (2009), vol. 5, pages 617 - 626 *
CIECKO-MICHALSKA I. et al., "Pathogenesis of Hepatic Encephalopathy", Gastroenterology Research and Practice (2012, vol. 2012, no. 642108, (2012), URL: https://www.hindawi.com/journals/grp/2012/642108/cta, (2016-12-08) *
CLÉMENT M.-A. et al, 50th Annual Meeting European Association for the Study of the Liver, Journal of Hepatology, (2015-04), vol. 62, no. Supplement 2, page S295 *
MARC ORIA; JORDI ROMERO-GIMNEZ; JOS ANTONIO ARRANZ; ENCARNACI RIUDOR; NRIA RAGUER; JUAN CRDOBA;: "Ornithine phenylacetate prevents disturbances of motor-evoked potentials induced by intestinal blood in rats with portacaval anastomosis", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 56, no. 1, 22 June 2011 (2011-06-22), AMSTERDAM, NL , pages 109 - 114, XP028341033, ISSN: 0168-8278, DOI: 10.1016/j.jhep.2011.06.026 *
MARIA JOVER-COBOS, LORETTE NOIRET, YALDA SHARIFI, RAJIV JALAN: "Ornithine phenylacetate revisited", METABOLIC BRAIN DISEASE, KLUWER ACADEMIC - PLENUM PUBLISHERS, NEW YORK, NY, US, vol. 28, no. 2, 1 June 2013 (2013-06-01), US , pages 327 - 331, XP055324717, ISSN: 0885-7490, DOI: 10.1007/s11011-013-9391-5 *
ROGER F. BUTTERWORTH: "Neuronal cell death in hepatic encephalopathy", METABOLIC BRAIN DISEASE, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NE, vol. 22, no. 3-4, 13 September 2007 (2007-09-13), Ne , pages 309 - 320, XP019554863, ISSN: 1573-7365, DOI: 10.1007/s11011-007-9072-3 *
ROMERO-GÓMEZ M. ET AL.: "Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure", JOURNAL OF HEPATOLOGY, vol. 62, no. 2, 2015, pages 437 - 447, DOI: doi:10.1016/j.jhep.2014.09.005 *
VENTURA-COTS M. ET AL.: "Safety of Ornithine Phenylacetate in Cirrhotic Decompensated Patients An Open-label, Dose-escalating, Single-cohort Study", JOURNAL OF CLINICAL GASTROENTEROLOGY, vol. 47, no. 10, Nov. 2013, pages 881 - 887 *

Also Published As

Publication number Publication date
JP6989495B2 (ja) 2022-01-05
WO2017053613A8 (en) 2017-04-27
AU2016325556A1 (en) 2018-03-01
EP3352748A4 (en) 2019-06-05
EP3352748A1 (en) 2018-08-01
US20200206174A1 (en) 2020-07-02
HK1257679A1 (zh) 2019-10-25
CA2998490A1 (en) 2017-03-30
WO2017053613A1 (en) 2017-03-30
JP2018531929A (ja) 2018-11-01

Similar Documents

Publication Publication Date Title
AU2016325556B2 (en) Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
US11873266B2 (en) Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke
Peng et al. Therapeutic time window and dose dependence of xenon delivered via echogenic liposomes for neuroprotection in stroke
Rani et al. In vitro and in vivo studies reveal the beneficial effects of chlorogenic acid against ER stress mediated ER-phagy and associated apoptosis in the heart of diabetic rat
Zhu et al. Verbascoside protects from LPS-induced septic cardiomyopathy via alleviating cardiac inflammation, oxidative stress and regulating mitochondrial dynamics
Sun et al. Scutellarin attenuates doxorubicin‐induced cardiotoxicity by inhibiting myocardial fibrosis, apoptosis and autophagy in rats
Saccà et al. A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2
Matsui et al. Dynamic analysis of histamine-mediated attenuation of acetylcholine-induced sweating via GSK3β activation
Zhou et al. Icariin improves oxidative stress injury during ischemic stroke via inhibiting mPTP opening
JP2018523683A (ja) Ｌ−オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる筋肉喪失の治療および予防
US20160346302A1 (en) Novel methods
Bartlett et al. Paraquat is excluded by the blood brain barrier in rhesus macaque: An in vivo pet study
Liang et al. Impaired autophagy and mitochondrial dynamics are involved in Sorafenib-induced cardiomyocyte apoptosis
Liang et al. Glycyrrhetinic acid triggers a protective autophagy by inhibiting the JAK2/STAT3 pathway in cerebral ischemia/reperfusion injury
Cavaglia et al. Increased transcription factor expression and permeability of the blood brain barrier associated with cardiopulmonary bypass in lambs
Tigani et al. Resolution of the oedema associated with allergic pulmonary inflammation in rats assessed noninvasively by magnetic resonance imaging
Migliati et al. Na+–K+–2Cl− cotransport inhibitor attenuates cerebral edema following experimental stroke via the perivascular pool of aquaporin-4
Harima et al. Effect of carvedilol against myocardial injury due to ischemia–reperfusion of the brain in rats
Vijikumar et al. Novel mitoNEET ligand NL-1 improves therapeutic outcomes in an aged rat model of cerebral ischemia/reperfusion injury
Rehni et al. Blockade of acid-sensing ion channels attenuates recurrent hypoglycemia-induced potentiation of ischemic brain damage in treated diabetic rats
Ye et al. Hesperetin alleviates neuronal pyroptosis by promoting mitophagy via DHCR24/BACE1 signaling pathway after subarachnoid hemorrhage in mice
Nguyen et al. Journal of Health Science and Development
Olguín et al. Treatment of pulmonary arterial hypertension using extemporaneous formulation of sildenafil in Mexican children
Win et al. JNK mediation of acetaminophen (APAP) hepatotoxicity is determined by Sab (SH3BP5) dependent dysregula-tion of intramitochondrial c-Src kinase: 49
HK1208363B (en) Compounds for use in the treatment of aquaporin-mediated diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)